> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # COVID-19 Clinical Pharmacology Task Group - URL: https://www.whiteroseintelligence.com/covid-19-clinical-pharmacology-task-group/ - Published: 1999-01-02T14:23:00.000Z - Updated: 2026-02-20T04:01:50.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #organization, COVID-19, Organization The **COVID-19 Clinical Pharmacology Task Group** (CPTG) was an *ad hoc* external advisory group convened by the [Public Health Agency of Canada](https://www.whiteroseintelligence.com/Public-Health-Agency-of-Canada) during the COVID-19 pandemic. The group's work concluded on March 30, 2021 officially "because of the welcome entry of effective and safe [vaccines](https://www.whiteroseintelligence.com/COVID-19-vaccine) to the Canadian health care system."[\[1\]](#fn1) ## Activities The group met several times and released statements on COVID-19 therapeutics. - Remdesivir: The CPTH “recommends that remdesivir should only be administered as part of a randomized controlled trial to monitor whether potential benefits of remdesivir outweigh known and potential risks in the treatment of patients hospitalized with COVID-19.”[\[2\]](#fn2) - Hydroxychloroquine: The CPTH “recommends against the use of hydroxychloroquine as a treatment for patients with COVID-19 due to negligible evidence of efficacy and significant potential for harm leading to a high risk to benefit ratio. This guidance is not meant to replace clinical judgement or specialist consultation.”[\[3\]](#fn3) - Dexamethasone: The CPTH “recommends that among hospitalized patients with COVID-19 who require supplemental oxygen or mechanical ventilation, dexamethasone 6 mg IV for 10 days (or until discharge, if earlier) or equivalent glucocorticoid dose should be strongly considered. This guidance is not meant to replace clinical judgment or specialist consultation.”[\[4\]](#fn4) ## Members | Name | Position | Notes | | ------------------------- | --------------------- | ------------------------------------------------------------------------------------------------------------- | | Marina Salvadori | Co-Chair[\[5\]](#fn5) | [Public Health Agency of Canada](https://www.whiteroseintelligence.com/Public-Health-Agency-of-Canada) (PHAC) | | Michael Rieder | Co-Chair | University of Western Ontario | | Marie Lordkipanidze | External Expert | University of Montreal | | Richard Hall | External Expert | Dalhousie University | | Micheline Piquette-Miller | External Expert | University of Toronto | | Abby Collier | External Expert | University of British Columbia (UBC) | | Srinivas Murthy | External Expert | University of British Columbia (UBC) | | Jonathan Kimmelman | External Expert | McGill University | --- 1. Public Health Agency of Canada. (2021, June 15). *COVID-19 Clinical Pharmacology Task Group.* Government of Canada. [↩︎](#fnref1) 2. Forbes, N., Patel, M., Rieder, M., & Salvadori, M. (2020, November 23). *Statement on remdesivir: Ad-hoc COVID-19 Clinical Pharmacology Task Group.* Government of Canada. [↩︎](#fnref2) 3. Forbes, N., Patel, M., Rieder, M., & Salvadori, M. (2020, October 22). *Statement on hydroxychloroquine: COVID-19 Clinical Pharmacology Task Group.* Government of Canada. [↩︎](#fnref3) 4. Forbes, N., Patel, M., Rieder, M., & Salvadori, M. (2020, November 23). *Statement on dexamethasone: COVID-19 Clinical Pharmacology Task Group.* Government of Canada. [↩︎](#fnref4) 5. Public Health Agency of Canada. (2021, June 15). *Ad-hoc COVID-19 Clinical Pharmacology Task Group: Terms of reference.* Government of Canada. [↩︎](#fnref5)